567.75
8.10 (1.45%)
| Previous Close | 559.65 |
| Open | 557.33 |
| Volume | 83,726 |
| Avg. Volume (3M) | 500,353 |
| Market Cap | 24,883,169,280 |
| Price / Earnings (TTM) | 20.39 |
| Price / Earnings (Forward) | 19.84 |
| Price / Sales | 8.42 |
| Price / Book | 3.46 |
| 52 Weeks Range | |
| Earnings Date | 29 Apr 2026 |
| Profit Margin | 40.44% |
| Operating Margin (TTM) | 48.19% |
| Diluted EPS (TTM) | 25.11 |
| Quarterly Revenue Growth (YOY) | 17.20% |
| Quarterly Earnings Growth (YOY) | 5.10% |
| Total Debt/Equity (MRQ) | 2.94% |
| Current Ratio (MRQ) | 5.46 |
| Operating Cash Flow (TTM) | 1.41 B |
| Levered Free Cash Flow (TTM) | 825.79 M |
| Return on Assets (TTM) | 12.93% |
| Return on Equity (TTM) | 19.94% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (US) | Mixed | Bullish |
| Drug Manufacturers - Specialty & Generic (Global) | Mixed | Bullish | |
| Stock | United Therapeutics Corporation | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 1.5 |
| Insider Activity | -5.0 |
| Price Volatility | -0.5 |
| Technical Moving Averages | 3.5 |
| Technical Oscillators | 4.0 |
| Average | 0.70 |
|
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Investment Style | Mid Core |
| % Held by Insiders | 1.75% |
| % Held by Institutions | 100.69% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 705.00 (UBS, 24.17%) | Buy |
| Median | 600.00 (5.68%) | |
| Low | 466.00 (Wells Fargo, -17.92%) | Hold |
| Average | 602.00 (6.03%) | |
| Total | 6 Buy, 1 Hold | |
| Avg. Price @ Call | 505.13 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Cantor Fitzgerald | 12 Mar 2026 | 625.00 (10.08%) | Buy | 532.82 |
| UBS | 05 Mar 2026 | 705.00 (24.17%) | Buy | 485.06 |
| HC Wainwright & Co. | 26 Feb 2026 | 600.00 (5.68%) | Buy | 503.60 |
| Oppenheimer | 26 Feb 2026 | 600.00 (5.68%) | Buy | 503.60 |
| RBC Capital | 26 Feb 2026 | 643.00 (13.25%) | Buy | 503.60 |
| TD Cowen | 26 Feb 2026 | 575.00 (1.28%) | Buy | 503.60 |
| Wells Fargo | 26 Feb 2026 | 466.00 (-17.92%) | Hold | 503.60 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| CAUSEY CHRISTOPHER | - | 588.36 | -1,300 | -764,868 |
| EDGEMOND JAMES | - | 576.59 | -20,000 | -11,531,700 |
| MAHON PAUL A | - | 564.81 | -8,300 | -4,687,923 |
| ROTHBLATT MARTINE A | - | 567.85 | -47,500 | -26,972,875 |
| Aggregate Net Quantity | -77,100 | |||
| Aggregate Net Value ($) | -43,957,366 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 571.73 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| MAHON PAUL A | Officer | 02 Apr 2026 | Automatic sell (-) | 8,300 | 564.81 | 4,687,923 |
| MAHON PAUL A | Officer | 02 Apr 2026 | Option execute | 8,300 | - | - |
| EDGEMOND JAMES | Officer | 02 Apr 2026 | Automatic sell (-) | 10,000 | 564.81 | 5,648,100 |
| EDGEMOND JAMES | Officer | 02 Apr 2026 | Option execute | 10,000 | - | - |
| ROTHBLATT MARTINE A | Officer | 02 Apr 2026 | Automatic sell (-) | 9,500 | 564.81 | 5,365,695 |
| ROTHBLATT MARTINE A | Officer | 02 Apr 2026 | Option execute | 9,500 | - | - |
| ROTHBLATT MARTINE A | Officer | 01 Apr 2026 | Automatic sell (-) | 9,500 | 570.27 | 5,417,565 |
| ROTHBLATT MARTINE A | Officer | 01 Apr 2026 | Option execute | 9,500 | - | - |
| ROTHBLATT MARTINE A | Officer | 31 Mar 2026 | Automatic sell (-) | 9,500 | 592.98 | 5,633,310 |
| ROTHBLATT MARTINE A | Officer | 31 Mar 2026 | Option execute | 9,500 | - | - |
| CAUSEY CHRISTOPHER | Director | 30 Mar 2026 | Automatic sell (-) | 1,300 | 588.36 | 764,868 |
| CAUSEY CHRISTOPHER | Director | 30 Mar 2026 | Option execute | 1,300 | - | - |
| EDGEMOND JAMES | Officer | 30 Mar 2026 | Automatic sell (-) | 10,000 | 588.36 | 5,883,600 |
| EDGEMOND JAMES | Officer | 30 Mar 2026 | Option execute | 10,000 | - | - |
| ROTHBLATT MARTINE A | Officer | 30 Mar 2026 | Automatic sell (-) | 9,500 | 588.36 | 5,589,420 |
| ROTHBLATT MARTINE A | Officer | 30 Mar 2026 | Option execute | 9,500 | - | - |
| ROTHBLATT MARTINE A | Officer | 27 Mar 2026 | Automatic sell (-) | 9,500 | 522.83 | 4,966,885 |
| ROTHBLATT MARTINE A | Officer | 27 Mar 2026 | Option execute | 9,500 | - | - |
| Show more | ||||||
| Date | Type | Details |
|---|---|---|
| 26 Jan 2026 | Announcement | United Therapeutics Announces Positive Results from Phase 1 Study of miroliverELAP® in Patients with Acute Liver Failure |
| 22 Jan 2026 | Announcement | United Therapeutics Corporation Announces Appointment of Kevin J. Tracey to its Board of Directors |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |